Breadcrumb

  1. Our vision
  2. About Santen
  3. Ophthalmology is our sole focus

Ophthamology is our sole focus

For 130 years, we’ve nurtured a deep knowledge of ocular health. All of our research, production and marketing is focused on this particular area. We apply our expertise to innovate and evolve treatments, responding directly to established and emerging patient needs. 

We refuse to be distracted into other areas of pharmaceutical development. Our chosen field of ophthalmology presents an enormous opportunity to improve patients’ quality of life. We make a conscious decision to ignore any short-term temptation to enter into other areas, because we won’t compromise our intense, long-term focus on ocular health and treatment possibilities.

Because of our specialist focus, patients and healthcare professionals can trust us to deliver the highest standards of quality and safety in ophthalmology treatments.

Our vocation to improve eye health

Vision is one of our most important senses. We depend on sight more than any other of our senses to move around and interact with the world around us. Even moderate visual problems can affect quality of life, reducing a person’s productivity, mobility and independence. We feel proud and privileged to focus all our efforts on the sense of sight and eye health.

That’s why our strategy is patient-driven: we seek opportunities and respond to demand for treatments and products that enhance people’s quality of life through improved vision and eye health. The potential to make a positive impact on patients’ lives through improved eye health is enormous: it’s estimated that 285 million people (4% of the world’s population) suffer from ophthalmic disorders worldwide.1

Moreover, there are still many countries and regions in the world where ophthalmic treatments are not widely available and where medical needs are unmet. We believe that Santen has the ability and responsibility to address these for patients and their loved ones.


References

  1. United Nations World Population Prospects: 2015